Entrada Therapeutics reports Q2 net loss of $42.8 million

Seeking Alpha··US·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Entrada Therapeutics reported a second-quarter net loss of $42.8 million, compared to a net loss of $43.1 million in the same quarter of 2025. Collaboration revenue fell to $0.9 million from $2 million a year earlier. As of June 30, 2026, the company held $223 million in cash, cash equivalents, and marketable securities, down from $295.7 million at the end of 2025.

Impact on assets 1

Biotech & Genomic Medicine▼ · 1 stocks
Entrada Therapeutics Inc
TRDA
▼ NegativeCapitalrelevance

Q2 net loss of $42.8 million and declining collaboration revenue, with cash reserves down from $295.7M to $223M.

© 2026 MarketIVNews